AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Source: When tendons are injured, tendon cells are activated to promote repair, but this process can be slow. Recent research has focused on improving tendon healing through therapies such as stem cell injections, growth factors, and tissue-engineered approaches to enhance tendon cell activity and regeneration.
Takaki's theory, while incorrectly focusing on macronutrients, was a step in the right direction that resulted in correct treatment. However, keen-eyed observers were able to easily rebut Takaki's theories with counterexamples, so nutritional theories remained heterodox science. In 1897, Christiaan Eijkman, a Dutch physician and pathologist, published his mid-1880s experiments showing that feeding unpolished rice (instead of the polished variety) to chickens helped to prevent beriberi. This was the first experiment to show that not a major chemical, but some minor nutrient, was the true cause of beriberi. The following year, Sir Frederick Hopkins postulated that some foods contained "accessory factors"—in addition to proteins, carbohydrates, fats, and salt—that were necessary for the functions of the human body. In 1901, Gerrit Grijns, a Dutch physician and assistant to Christiaan Eijkman in the Netherlands, correctly interpreted beriberi as a deficiency syndrome, and between 1910 and 1913, Edward Bright Vedder established that an extract of rice bran is a treatment for beriberi. In 1929, Eijkman and Hopkins were awarded the Nobel Prize for Physiology or Medicine for their discoveries. In 1935, Robert R. Williams isolated and cheaply synthesized thiamine from rice bran, based on discoveries he had made as a researcher in Manila's Bureau of Science in 1910. Williams assigned the patents to a fund that worked to promote thiamine-enriched rice in Asia, and in Bataan in particular.
Obese individuals are predisposed to developing osteoarthritis, not only due to the excess mechanical load, but also due to the excess expression of soluble factors, that is, leptin and pro-inflammatory cytokines, which contribute to joint inflammation and cartilage destruction. As such, obese individuals are in an altered state, due to a metabolic insufficiency, which requires specific nutritional treatment capable of normalising the leptin production and reducing the systematic low-level inflammation, in order to reduce the harmful impact of these systematic mediators on the joint health.
Sources: en.wikipedia.org
Insulin receptor substrate 4 is a protein that in humans is encoded by the IRS4 gene. IRS4 encodes the insulin receptor substrate 4, a cytoplasmic protein that contains many potential tyrosine and serine/threonine phosphorylation sites. Tyrosine-phosphorylated IRS4 protein has been shown to associate with cytoplasmic signalling molecules that contain SH2 domains. The IRS4 protein is phosphorylated by the insulin receptor tyrosine kinase upon receptor stimulation.
==== Apoptosis ==== Caspases are an important group of proteases involved in apoptosis or programmed cell death. The precursors of caspase, procaspase, may be activated by proteolysis through its association with a protein complex that forms apoptosome, or by granzyme B, or via the death receptor pathways.
After the 2020 presidential election, Kennedy and 11 other Republican senators said they would object to certain states' electoral votes in the 2021 United States Electoral College vote count on January 6, 2021, unless the vote was audited. He was participating in the certification when Trump supporters stormed the United States Capitol. Kennedy called the attack "despicable and shameful" and called for the rioters "to go to jail and pay for the destruction they caused." When the Capitol was secured and Congress returned to complete the certification, he objected to the certification of Arizona's electoral votes. On February 9, 2021, Kennedy voted against Trump's second impeachment. Kennedy said the impeachment effort was unconstitutional because Trump was no longer president. He called the impeachment process "a thinly veiled effort by the uber-elites in our country, who look down on most Americans, to denigrate further those people who chose to vote for President Trump and not vote for President Biden." On March 6, 2021, Kennedy voted against the American Rescue Plan Act of 2021, a COVID-19 recovery package. He said he voted against it because it was "an orgy of pork", adding, "This is not a coronavirus bill, not the way it's been portrayed". On May 28, 2021, Kennedy voted against the January 6 commission House Speaker Nancy Pelosi proposed to investigate the January 6 attack. The commission failed to gain traction, but the House later successfully established the January 6 committee as an alternative.
== References == Brendon, Piers (2010). The Decline and Fall of the British Empire, 1781–1997 (1st Vintage books ed.). New York City: Vintage Books. ISBN 9780307388414. Cilliers, Jakkie (1985). Counter-Insurgency in Rhodesia (PDF). Beckenham, United Kingdom: Croom Helm. ISBN 0-7099-3412-2. Cline, Lawrence E. (2005). "Pseudo Operations and Counterinsurgency: Lessons from Other Countries" (PDF). Strategic Studies Institute, US Army War College. Cross, G. (2017). Dirty War: Rhodesia and Chemical Biological Warfare, 1975–1980. Helion & Company. ISBN 978-1-911512-12-7. Dzimbanhete, Jephias Andrew (March 2017). "Reverberations of Rhodesian Propaganda in Narratives of Zimbabwe's Liberation War". Journal of Pan African Studies. 10 (1): 295–307. Evans, Michael (June 2007). "The Wretched of the Empire: Politics, Ideology and Counterinsurgency in Rhodesia, 1965–80". Small Wars & Insurgencies. 18 (2): 175–195. doi:10.1080/09574040701400601. S2CID 144153887. Gatchel, Theodore L. (2008). "Pseudo Operations – A Double Edged Sword of Counterinsurgency". In Norwitz, Jeffery H. (ed.). Armed Groups: Studies in National Security, Counterterrorism, and Counterinsurgency. Newport, Rhode Island: US Naval War College. pp. 61–74. ISBN 9781884733529. Martinez, Ian (December 2002). "The History of the Use of Bacteriological and Chemical Agents during Zimbabwe's Liberation War of 1965–80 by Rhodesian Forces". Third World Quarterly. 23 (6): 1159–1179. doi:10.1080/0143659022000036595. ISSN 0143-6597. JSTOR 3993569. S2CID 145729695. McLaughlin, Peter (August 1991).
Sources: en.wikipedia.org
These enzymes are synthesized as precursors or propeptides, which cleave themselves by an autoproteolytic reaction. The self-cleaving nature of asparagine peptide lyases contradicts the general definition of an enzyme given that the enzymatic activity destroys the enzyme. However, the self-processing is the action of a proteolytic enzyme, notwithstanding the enzyme is not recoverable from the reaction.
=== Legal rights === Depending upon the era and the country, slaves sometimes had a limited set of legal rights. For example, in the Province of New York, people who deliberately killed slaves were punishable under a 1686 statute. And, as already mentioned, certain legal rights were attached to the nobi in Korea, to slaves in various African societies, and to black female slaves in the French colony of Louisiana. Giving slaves legal rights has sometimes been a matter of morality, but also sometimes a matter of self-interest. For example, in ancient Athens, protecting slaves from mistreatment simultaneously protected people who might be mistaken for slaves, and giving slaves limited property rights incentivized slaves to work harder to get more property.
=== Growth Factors === Growth Factor enhanced grafts are produced using recombinant DNA technology. They consist of either Human Growth Factors or Morphogens (Bone Morphogenic Proteins in conjunction with a carrier medium, such as collagen).
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.